Anti-158P1D7 (clone Hal5-10acl2)-vc-MMAE ADC (CAT#: ADC-040CL)

• Antibody Overview
• Anti-158P1D7 Hal5-10acl2. MAbs to 158P1D7 were generated using XenoMouse technology® (Amgem
  
  Fremont) wherein the Murine Heavy and kappa Light chain loci have been inactivated and a majority of the Human Heavy and kappa Light chain immunoglobulin loci have been inserted. The MAb designated Hal5-10acl2 was generated from immunization of Human γ2 producing
  
  XenoMice with recombinant 3T3 cells expressing 158P1D7.

• Clone
• Hal5-10acl2

• Linker
• VC (valine-citrulline)

• Linker Class/Description
• Class: Enzymatically cleavable linkers-Peptide linkers
  Description: peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.

• Drug
• MMAE (Monomethyl auristatin E)

• Drug Class/Description
• Class: Auristatin
  Description: Auristatins are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

• Introduction
• 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in Glioblastoma, Lung, Bladder, Breast cancers.

Select a product category from the dropdown menu below to view related products.